MX352796B - Proteina de fusion anticancerigena. - Google Patents

Proteina de fusion anticancerigena.

Info

Publication number
MX352796B
MX352796B MX2014008028A MX2014008028A MX352796B MX 352796 B MX352796 B MX 352796B MX 2014008028 A MX2014008028 A MX 2014008028A MX 2014008028 A MX2014008028 A MX 2014008028A MX 352796 B MX352796 B MX 352796B
Authority
MX
Mexico
Prior art keywords
domain
fusion protein
sequence
terminus
amino acid
Prior art date
Application number
MX2014008028A
Other languages
English (en)
Other versions
MX2014008028A (es
Inventor
Sebastian Dominik Pawlak
Bartlomiej Maciej Zerek
Piotr Kamil Rózga
Jerzy Szczepan Pieczykolan
Original Assignee
Adamed Sp Zoo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adamed Sp Zoo filed Critical Adamed Sp Zoo
Publication of MX2014008028A publication Critical patent/MX2014008028A/es
Publication of MX352796B publication Critical patent/MX352796B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/32—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bacillus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43563—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43563—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects
    • C07K14/43572—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects from bees
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/461—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from fish
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/463—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from amphibians
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C07K7/086—Bombesin; Related peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16033—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/04—Phosphoric diester hydrolases (3.1.4)
    • C12Y301/04003—Phospholipase C (3.1.4.3)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Insects & Arthropods (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención se refiere a una proteína de fusión que comprende el dominio (a) que es un fragmento funcional de la secuencia de la proteína soluble hTRAIL, fragmento el cual comienza con un aminoácido en la posición no menor que hTRAIL95, o un homólogo de dicho fragmento funcional que tiene por lo menos 70% de identidad de secuencia, preferiblemente 85% de identidad y que termina con el aminoácido en la posición hTRAIL281, y por lo menos un dominio (b) que es una secuencia de un efector de péptido citolítico formador de poros en la membrana celular, en donde la secuencia del dominio (b) está unida al extremo C o extremo N del dominio (a); la proteína de fusión se puede usar para el tratamiento de enfermedades cancerígenas.
MX2014008028A 2011-12-28 2012-12-22 Proteina de fusion anticancerigena. MX352796B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PL397595A PL223487B1 (pl) 2011-12-28 2011-12-28 Przeciwnowotworowe białko fuzyjne
PCT/IB2012/057657 WO2013098755A2 (en) 2011-12-28 2012-12-22 Anticancer fusion protein

Publications (2)

Publication Number Publication Date
MX2014008028A MX2014008028A (es) 2014-08-21
MX352796B true MX352796B (es) 2017-12-07

Family

ID=47716118

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014008028A MX352796B (es) 2011-12-28 2012-12-22 Proteina de fusion anticancerigena.

Country Status (28)

Country Link
US (1) US20140377216A1 (es)
EP (1) EP2797950B1 (es)
JP (1) JP6324905B2 (es)
KR (1) KR20140110017A (es)
CN (1) CN103987728B (es)
AU (1) AU2012360086B2 (es)
BR (1) BR112014015922A2 (es)
CA (1) CA2859494A1 (es)
CY (1) CY1120055T1 (es)
DK (1) DK2797950T3 (es)
EA (1) EA201491277A1 (es)
ES (1) ES2655828T3 (es)
HK (1) HK1201848A1 (es)
HR (1) HRP20180012T1 (es)
HU (1) HUE035794T2 (es)
IL (1) IL232834A (es)
LT (1) LT2797950T (es)
MX (1) MX352796B (es)
NO (1) NO2797950T3 (es)
PH (1) PH12014501363A1 (es)
PL (2) PL223487B1 (es)
PT (1) PT2797950T (es)
RS (1) RS56758B1 (es)
SG (1) SG11201403282QA (es)
SI (1) SI2797950T1 (es)
UA (1) UA115436C2 (es)
WO (1) WO2013098755A2 (es)
ZA (1) ZA201405460B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014141094A1 (en) 2013-03-14 2014-09-18 Adamed Sp. Z O.O. Anticancer conjugate
GB201406705D0 (en) 2014-04-15 2014-05-28 Univ Liverpool Fusion proteins,polynucleotides,expression vectors, and their uses
US10428132B2 (en) 2015-02-11 2019-10-01 West China Hospital, Sichuan University Tumor necrosis factor-related apoptosis-inducing ligand variant, as well as a preparation method and use thereof
CN107216385A (zh) * 2017-05-19 2017-09-29 何向锋 肿瘤特异性重组水蛭素及其制备方法和用途
CN109400711B (zh) * 2017-05-31 2022-02-08 四川大学华西医院 一种PDGFRβ靶向性肿瘤坏死因子相关凋亡诱导配体变异体及其制备方法和用途
US11633363B2 (en) * 2017-09-27 2023-04-25 Emory University Fusion proteins having a toxin and cancer marker, nanoparticles, and uses related thereto
CN111909275A (zh) * 2019-05-08 2020-11-10 上海大学 延长多肽药物循环半衰期的靶向载药体系及其构建方法
CN110669146B (zh) * 2019-10-24 2023-05-23 常州大学 一种可特异性阻断衔接蛋白Nck的结合位点用于预防肠道EPEC感染的活性肽
KR102659285B1 (ko) * 2020-08-11 2024-04-22 경북대학교 산학협력단 암세포 유래 엑소좀에 선택적으로 결합하는 펩타이드 및 이의 용도
CN114031673B (zh) * 2021-12-22 2023-09-22 杭州长龄生物科技有限公司 一种多肽及其制备方法
CN114605517B (zh) * 2022-05-12 2022-09-27 广东海洋大学 一种具有广谱抗癌作用的多肽lxp-7及其应用
CN116063389B (zh) * 2022-08-23 2023-07-07 广州医科大学 递送核酸药物的多肽载体、治疗肿瘤的核酸药物及其制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994025616A1 (en) 1993-04-28 1994-11-10 Worcester Foundation For Experimental Biology Cell-targeted lytic pore-forming agents
US5763223A (en) 1995-06-29 1998-06-09 Immunex Corporation DNA encoding a cytokine that induces apoptosis
US6284236B1 (en) * 1995-06-29 2001-09-04 Immunex Corporation Cytokine that induces apoptosis
JP4688678B2 (ja) 2003-11-03 2011-05-25 北京沙東生物技術有限公司 抗癌作用を有する組換えタンパク質、それをコードする遺伝子、及びそれらの使用
CN1256347C (zh) * 2003-12-10 2006-05-17 中国人民解放军第二军医大学 激肽原第五结构域－肿瘤坏死因子相关凋亡诱导配体的融合蛋白及其制法和用途
ATE533058T1 (de) 2005-08-16 2011-11-15 Genentech Inc Apoptosesensitivität gegenüber apo2l/trail mittels testen auf galnac-t14-expression in zellen/gewebe
US20090131317A1 (en) 2007-06-22 2009-05-21 Affymax, Inc. Compounds and peptides that bind the trail receptor
GB0723059D0 (en) 2007-11-23 2008-01-02 Nat Univ Ireland Improved cytokine design
GB0724532D0 (en) 2007-12-17 2008-01-30 Nat Univ Ireland Trail variants for treating cancer
PT2252627T (pt) * 2008-01-24 2017-07-24 Esperance Pharmaceuticals Constructos de fusão de domínio lítico e métodos para produzir e utilizar os mesmos
WO2009140469A2 (en) 2008-05-14 2009-11-19 Genentech, Inc. Methods of using apo2l/trail to treat cancer

Also Published As

Publication number Publication date
DK2797950T3 (en) 2018-01-22
CA2859494A1 (en) 2013-07-04
LT2797950T (lt) 2018-02-12
EA201491277A1 (ru) 2014-09-30
RS56758B1 (sr) 2018-04-30
CN103987728B (zh) 2017-05-10
WO2013098755A3 (en) 2013-08-29
PL397595A1 (pl) 2013-07-08
WO2013098755A2 (en) 2013-07-04
IL232834A (en) 2017-09-28
NO2797950T3 (es) 2018-03-17
PH12014501363A1 (en) 2014-09-22
EP2797950B1 (en) 2017-10-18
HUE035794T2 (en) 2018-05-28
PL2797950T3 (pl) 2018-03-30
CY1120055T1 (el) 2018-12-12
MX2014008028A (es) 2014-08-21
SI2797950T1 (en) 2018-02-28
IL232834A0 (en) 2014-07-31
PT2797950T (pt) 2018-01-24
KR20140110017A (ko) 2014-09-16
JP6324905B2 (ja) 2018-05-16
ZA201405460B (en) 2015-04-29
JP2015504052A (ja) 2015-02-05
UA115436C2 (uk) 2017-11-10
SG11201403282QA (en) 2014-07-30
PL223487B1 (pl) 2016-10-31
EP2797950A2 (en) 2014-11-05
AU2012360086A1 (en) 2014-08-07
AU2012360086B2 (en) 2016-12-22
CN103987728A (zh) 2014-08-13
HK1201848A1 (en) 2015-09-11
US20140377216A1 (en) 2014-12-25
ES2655828T3 (es) 2018-02-21
BR112014015922A2 (pt) 2020-10-27
NZ627445A (en) 2016-01-29
HRP20180012T1 (hr) 2018-02-09

Similar Documents

Publication Publication Date Title
UA115436C2 (uk) Протираковий злитий протеїн
PH12014501083A1 (en) Anticancer fusion protein
MX2013007872A (es) Proteina de fusion anticancer.
MX2013006213A (es) Proteina de funsion anticancer.
WO2013152351A3 (en) Fusion polypeptides and methods of use thereof
MX360208B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX363136B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX360211B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
CY1116099T1 (el) Πρωτεϊνη συντηξης κατα του καρκινου
NZ629843A (en) Identification of channelrhodopsin-2 (chop2) mutations and methods of use
MX2020010399A (es) 3-epimerasa.
MX359449B (es) Conjugados de anticuerpo fármaco anti-cd70.
NZ603196A (en) Methods of use of soluble cd24 for therapy of rheumatoid arthritis
WO2012143477A3 (en) Anticancer fusion protein
WO2016004906A3 (zh) 一种肿瘤血管阻断剂多肽、基因、表达载体及其应用
PH12018502451A1 (en) Brain delivery protein
MX2014004953A (es) Ligadores basados en tirosina para la conexion desprendible de peptidos.
EP2552462A4 (en) CCN3 PEPTIDES AND ANALOGS THEREOF FOR THERAPEUTIC USE
EP4361634A3 (en) Methods for treating and monitoring the status of cancer
WO2011135222A3 (fr) Utilisation de peptides comme transporteurs destines a l'internalisation de molecules d'interet dans des cellules cibles
WO2015001045A3 (en) Pro-apoptotic ras and raf peptides
GB0818080D0 (en) Immunogenic peptides
PH12014502198A1 (en) Osteoprotegerin derived composition and use thereof
AR079370A1 (es) Uso de peptidos antimicrobianos para el tratamiento de infeccion urinaria/cistitis
UA108911C2 (xx) Протираковий злитий протеїн

Legal Events

Date Code Title Description
FG Grant or registration